New research on ALS opens up for early treatment
- The MIROCALS Phase 2b clinical trial tested adding low-dose IL-2 to riluzole in 220 ALS patients over nearly two years in France.
- The study aimed to improve survival since ALS causes motor neuron damage and riluzole only slows disease progression.
- IL-2 was safe and linked to a 19% nonsignificant overall death risk reduction, but patients with low spinal pNFH had a significant 48% decreased death risk.
- Co-Author Andrea Malaspina called publication of these results "a milestone in the progress toward novel treatments and the understanding of biomarkers in ALS trials."
- These findings support IL-2's potential to improve survival in specific ALS patients, but researchers emphasize further studies are needed to confirm benefits.
16 Articles
16 Articles


Funding for research on ALS and other diseases must not be halted
Researchers are being hampered by Trump administration cuts.
New research on ALS opens up for early treatment
Using the gene scissors CRISPR and stem cells, researchers have managed to identify a common denominator for different gene mutations that all cause the neurological disease ALS. The research shows that ALS-linked dysfunction occurs in the energy factories of nerve cells, the mitochondria, before the cells show other signs of disease, which was not previously known.
Medications that suppress REM sleep improve survival in amyotrophic lateral sclerosis patients
During REM sleep, the body enters a state of paralysis. This can pose a danger for patients with weakened diaphragms due to neuromuscular diseases. Now new research published at the ATS 2025 International Conference has shown that antidepressants that suppress REM sleep are associated with improved survival in people with amyotrophic lateral sclerosis (ALS).

An Experimental Drug May Benefit some Patients with a Rare Form of ALS.
The drug has been tested with a rare form of ALS caused by a mutation in a gene called FUS, which is responsible for between 1% and 2% of cases of the disease, but which causes some of the most aggressive forms and begins in adolescents and young adults.
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage